The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1379
December 12, 2011
View Complete Issue         Table of Contents 2019 
Rivaroxaban (Xarelto) for Acute Coronary Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rivaroxaban (Xarelto) for Acute Coronary Syndrome
December 12, 2011 (Issue: 1379)
The standard antithrombotic therapy for treatment of patients with acute coronary syndrome (ACS) is dual antiplatelet therapy with aspirin and clopidogrel (Plavix) or another thienopyridine, plus a parenteral anticoagulant while the patient is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rivaroxaban (Xarelto) for Acute Coronary Syndrome
Article code: 1379a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.